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It has been proposed that iron depletion protects against cardiovascular disease. There is increasing evidence
that one mechanism for this protection may involve a reduction in iron levels within atherosclerotic plaque.
Large increases in iron concentration are seen in human atherosclerotic lesions in comparison to levels in
healthy arterial tissue. In animal models, depletion of lesion iron levels in vivo by phlebotomy, systemic iron
chelation treatment or dietary iron restriction reduces lesion size and/or increases plaque stability. A number
of factors associated with increased arterial disease or increased cardiovascular events is also associated with
increased plaque iron. In rats, infusion of angiotensin II increases ferritin levels and arterial thickness which
are reversed by treatment with the iron chelator deferoxamine. In humans, a polymorphism for haptoglobin
associated with increased cardiovascular disease is also characterized by increased lesional iron. Heme
oxygenase 1 (HO1) is an important component of the system for mobilization of iron from macrophages.
Human HO1 promoter polymorphisms causing weaker upregulation of the enzyme are associated with
increased cardiovascular disease and increased serum ferritin. Increased cardiovascular disease associated
with inflammation may be in part caused by elevated hepcidin levels that promote retention of iron within
plaque macrophages. Defective retention of iron within arterial macrophages in genetic hemochromatosis
may explain why there is little evidence of increased atherosclerosis in this disorder despite systemic iron
overload. The reviewed findings support the concept that arterial plaque iron is a modifiable risk factor for
atherogenesis.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Nearly three decades ago, it was suggested that a state of sustained
iron depletion or mild iron deficiency exert a primary protective
action against ischemic heart disease [1–8]. This “iron hypothesis”was
offered as an explanation of the sex difference in coronary disease
incidence and the increase in incidence among women after
menopause. Despite significant controversy, the idea has achieved
standing as a plausible and testable hypothesis [9–13]. A protective
effect of iron depletion that may have multiple beneficial conse-
quences is decreased availability of redox-active iron in vivo [2,14].
It has been proposed that the amount of free iron available at sites
of oxidative or inflammatory injury is a function of the stored iron
level and that the availability of redox-active iron in vivo approaches
its minimum in the state of iron depletion. There is significant
experimental support for this concept [14–35]. In particular, it has
been shown that removal of stored iron from the body can decrease
the amount of iron depositionwithin atherosclerotic lesions in animal
studies. Depletion of lesion iron levels in vivo by phlebotomy, systemic
iron chelation treatment or dietary iron restriction reduces lesion size
in these studies and increases plaque stability [18,31,36–38]. The
original formulation of the iron hypothesis did not specify a
mechanism. There may well be multiple mechanisms by which iron
depletion protects against heart disease. This animal work as well as a
number of more recent studies focuses attention on pathogenic roles
for ironwithin arterial plaque. Iron is present in atherosclerotic plaque
at concentrations that appreciably exceed that found in healthy
arterial tissue. This iron is not simply an inert component of plaque.
Some of the arterial iron is redox active and the ferritin- and
hemosiderin-bound iron compartment remains a reservoir of poten-
tially reactive iron within lesions. Does this iron have a role in the
production of clinical events? Does it affect plaque stability? Are there
any modalities that can decrease the concentration of plaque iron?
Would such removal of plaque iron by induced iron deficiency or
treatment with iron chelators decrease plaque vulnerability? There
have now been a number of studies that provide evidence for one
potential mechanism by which iron depletion may protect against
atherothrombotic disease. This article will review that work and its
relevance to the iron hypothesis.
2. Presence and modifiability of plaque iron: Early work in animal
models and in human studies
In a 1992 study, Smith et al. [39] demonstrated the presence of
catalytic iron in material taken from human atherosclerotic lesions,
providing important indirect support for the iron hypothesis. Iron
deposits in atherosclerotic lesions in the cholesterol-fed rabbit were
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later confirmed by nuclear microscopy and in human lesions by
conventional histologic staining [38,40].
Matthews et al. [41] observed a large and significant decrease in
total aorta cholesterol concentration after iron chelator treatment in
cholesterol-fed rabbits and suggested that “perhaps [deferiprone]
functions to remove free iron in the vascular subendothelium” . They
did not directly assess the effects of iron chelationwith deferiprone on
vascular iron concentration.
In a series of studies,Watt, Halliwell and colleagues [31,37,38,40,42]
used nuclear microscopy to demonstrate a 7 fold increase in iron
concentration within newly formed atherosclerotic lesions compared
to healthy artery tissue in New ZealandWhite rabbits fed a 1% choles-
terol diet. Iron accumulation was noted to occur at the onset of lesion
formation. Repeated bleeding that decreased iron uptake in the artery
wall delayed the onset of atherogenesis. In other experiments, daily
treatmentswith the iron chelator deferoxamine for 9weeks decreased
the average lesion iron level from 95 ppm dry wt to 58 ppm dry wt
(p=0.030) and also significantly reduced average lesion area
(p=0.038). These findings provided direct evidence for a key role of
iron in initiating atherogenesis.
In a seminal study, Chau and colleagues [43] differentially screened
a cDNA library of human atherosclerotic aorta and discovered that
genes for the iron-storage proteins, L-ferritin and H-ferritin, are highly
expressed in human atherosclerotic plaques. In situ hybridization
revealed that both L- and H-ferritin mRNAs were induced both in
endothelial cells and macrophages of early human lesions. In
advanced human lesions, the signals were also detected in the
vascular smooth muscle cells (VSMC). Lesions in atherosclerotic
aortas from rabbits fed a high cholesterol diet showed similar
increased expression of ferritin genes. There was a close temporal
association between lesion formation and increased ferritin gene
expression in the rabbit aortas. Ferritin gene induction occurred early
in lesion development, before the increased risk of intralesional
hemorrhage seen in advanced, complex lesions.
Subsequently, these investigators found stainable iron deposits in
atherosclerotic lesions in apolipoprotein E deficient (apoE-deficient)
mice [18]. Stainable iron increased with age in atherosclerotic lesions
as well as in heart and liver. In young mice receiving a low- iron diet
for 3 months, stainable iron and iron content were much less in aortic
tissues than in littermates fed standard iron replete chow. Athero-
sclerotic lesions were significantly smaller in the iron restricted
animals and circulating autoantibodies to oxidized LDL were sig-
nificantly lower. A later study by this group using the same apoE-
deficient mouse model indicated that decreased arterial iron content
was associated with lower expression of matrix metalloproteinase-9
(MMP-9), increased lesional collagen content and increased plaque
stability [36].
The findings of Chau and colleagues on increased ferritin gene
expression in VSMC of advanced human lesions [43] are consistent
with the possibility that iron may be involved in the control of
VSMC growth in myoproliferative intima lesions. An early study by
Porreca et al. [44] directly supports this possibility. They examined
the effect of the iron chelator, deferoxamine (DFO), on VSMC
proliferation in a carotid balloon injury model in the rabbit. Intimal
thickening and VSMC proliferation were significantly inhibited by
DFO treatment.
Dabbagh et al. [45] investigated the effects of iron removal by
phlebotomy or iron overload by intraperitoneal iron dextran on aortic
atherosclerosis in the cholesterol-fed rabbit. They did not observe a
significant effect of either intervention on lesion area. However,
analysis of aortic iron content demonstrated that neither intervention
succeeded in achieving a significant effect on aortic iron content in
comparison with control aortas, despite producing significant differ-
ences in liver iron. The absence of an effect of this phlebotomy
protocol on aortic iron likely explains the failure of these investigators
to observe an effect of iron removal on lesion area.
3. Iron in human carotid lesions
Using electron paramagnetic resonance (EPR) spectroscopy and
inductively coupled plasma mass spectroscopy (ICPMS) Davies and
colleagues [46] quantified iron in ex vivo carotid lesions and in healthy
human arteries. They found elevated levels of iron in the intima of
lesions compared with healthy controls (0.370 versus 0.022 nmol/mg
tissue by EPR, 0.525 versus 0.168 nmol/mg tissue by ICPMS, P pb0.05
in both cases). Cholesterol levels in lesions correlated positively with
iron accumulation. In later work [47], iron levels in human athero-
sclerotic plaque correlated positively and strongly with multiple
markers of protein oxidation, but not with markers of lipid oxidation.
Lapenna et al. [48] studied the relationship between serum ferritin
and low molecular weight iron (LMWI) in ex vivo carotid endarter-
ectomy specimens. They found a significant correlation of LMWI in
these atherosclerotic specimens with serum ferritin. They also reported
an association of plaque LMWIwithmarkers of lipid peroxidation in the
largest subgroup of patients with b90% stenosis. In a small subgroup of
patients with N90% stenosis the association of LMWI and lipid
peroxidation markers did not achieve significance. The correlation of
lesional LMWI with serum ferritin is consistent with the possibility that
the concentration of redox-active ironwithin atherosclerotic lesions can
be lowered by depletion of body iron stores.
Yuan and colleagues [11,49–56] documented the presence of iron
in atherosclerotic vascular tissue, suggested erythrophagocytosis as an
important source of this iron, and considered the role of such iron in
increasing the intralesional concentration of redox-active iron. They
explored the interactions of iron and lipoproteins as plaque macro-
phages progress to apoptotic foam cells. In a recent study of 52 ex vivo
human carotid atherosclerotic lesions [8], they found that transferrin
receptor 1 (TfR1) expression was positively correlated with macro-
phage infiltration, ectopic lysosomal cathepsin L and ferritin expres-
sion. Highly expressed TfR1 and ferritin in CD68 positive macrophages
were significantly associated with development and severity of
human carotid plaques, smoking and patient's symptoms. The
findings suggested that pathologic macrophage iron metabolism
may contribute to vulnerability of human atheroma, established risk
factors and their clinical symptoms.
4. Angiotensin II and arterial iron deposition
Ishizaka et al. [57] found that angiotensin II infusion for 7 days in
rats caused a N20-fold increase in ferritin protein expression over
control values in aortic endothelial and adventitial cells, including
monocytes/macrophages. Stainable iron was seen in the adventitial
layer of aorta from angiotensin II infused animals. Iron chelation
suppressed aortic induction of ferritin and heme oxygenase-1 (HO1)
and suppressed upregulation of mRNA levels of monocyte chemoat-
tractant protein-1 (MCP1). In addition, iron chelation attenuated the
medial thickening and perivascular fibrosis induced by a 4 week
infusion of angiotensin II. Mazzolai et al. [58] using an apoE-deficient
mouse model system demonstrated that high endogenous angioten-
sin II is associated with the development of unstable atherosclerotic
plaques. Taken together, these two studies support the concept that
increased arterial iron promotes plaque instability.
5. Haptoglobin polymorphisms and plaque iron content
Asleh et al. [59] suggested that hemoglobin within plaque derived
from microvascular hemorrhage is cleared more slowly from plaques
associated with haptoglobin (Hp) 2-2 genotype as compared to Hp 1-
1 plaques. The Hp 2-2 genotype is associated with an increased risk of
atherosclerotic cardiovascular disease. These investigators then
created a type 2 Hp allele in the apoE-deficient mouse and explored
the effect of Hp 2-2 genotype on iron, lipid peroxidation and
macrophage accumulation in plaque. They found that “intra-plaque
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hemorrhage generates greater iron deposition inmicewith the Hp 2-2
genotype, leading to increased oxidation of lipids and other cellular
constituents of the plaque.” Slower clearance of hemoglobin-derived
iron within lesions, in this case because of an Hp polymorphism,
causes increased lipid peroxidation and macrophage accumulation in
atherosclerotic lesions. In a later study [60], they found impaired
clearance of free hemoglobin and iron from atherosclerotic plaques in
Hp 2-2 diabetic patients. They concluded that Hp genotype is a major
determinant of the iron concentration of atheroscerotic plaque iron
derived from intralesional hemorrhage.
6. Heme oxygenase-1 polymorphisms and plaque iron
A similar patternmay occurwith promoter polymorphisms in HO1,
an inducible enzyme that catalyzes the rate limiting step in heme
catabolism. Heme catabolism is a key function in mobilizing macro-
phage iron derived from ingested erythrocytes. Alterations in the
activity of HO1 influence the rate of clearance of hemoglobin-derived
iron from macrophages. In the HO1 deficient mouse (HO1−/−)
conspicuous iron loading is seen in Kupffer cells, hepatocytes, hepatic
vascular tissue, and renal cortical tubules [61]. In another study
involving HO1−/− mice, increased levels of reactive oxygen species
production inmacrophages and increased atherosclerotic plaquewere
thought to be a result of relatively decreased intracellular levels of
biliverdin or bilirubin, or increased intracellular levels of iron stores
[62]. Pharmacologic inhibition of HO1 is associated with marked
elevation in serum ferritinwithout significant changes in several other
acute phase reactants [63].
In diabetic humans, HO1 promoter polymorphisms causing
weaker upregulation of the enzyme are associated with both
increased cardiovascular disease [64] and with significantly increased
serum ferritin [65]. Taken together, these findings are consistent with
the concept that slower clearance of hemoglobin-derived iron may
promote atherosclerotic plaque progression.
Statins have been reported to induce HO1 in murine macrophages
[66] and in human endothelial cells [67] raising the possibility that this
may be a basis for the protective actions of statins independently of their
cholesterol lowering effect. It has been proposed that statins may
stabilize atherosclerotic plaques in part by inducing intralesional HO1,
facilitating ironmobilization, and thereby loweringplaque iron levels [7].
7. Quantitation of carotid plaque iron by MRI based T2⁎
measurement
Raman et al. [68] investigated the role of iron deposition in carotid
plaque instability using a novel approach of in vivo plaque character-
ization by a noninvasive, noncontrast magnetic resonance based T2⁎
measurement. The method was validated using ex vivo plaque analyses
of intra-plaque iron composition. Symptomatic patients had signifi-
cantly shorter plaque T2⁎ values (20.0±1.8 ms) compared with
asymptomatic patients (34.4±2.7 ms, pb0.001), respectively, which
is consistent with a shift in iron from low molecular weight Fe(III) to
greater amounts of T2⁎-shortening forms of iron. Such T2⁎ shortening
forms were thought to be iron aggregates represented by hemosiderin
and ferritin. Symptom-producing plaques demonstrated characteristic
changes in iron forms by ex vivo analysis. The findings support the
dynamic presence of iron in the microenvironment of atherosclerotic
plaque. Additional studies are needed to better characterize the
significance of the various forms of iron within plaque and to assess
the clinical utility of noninvasive measures of plaque iron in the clinical
determination of plaque stability.
8. Inflammation, IL-6, hepcidin and iron in arterial plaque
Hepcidin level is a major determinant of the amount of iron
retained within macrophages [69–72]. Production of hepcidin is
regulated by a number of interrelated factors. Elevated levels, which
favor macrophage iron retention, are encountered with increased iron
intake, infection and inflammation. Reduced hepcidin levels are
associated with iron deficiency, hypoxia, anemia and homozygous
hemochromatosis. Interleukin 6 (IL-6) upregulation as seen in
inflammatory states induces hepcidin synthesis [69].
Hepcidin production is regulated over a large concentration range.
In one recent study [73], urine concentrations of hepcidin were
reduced by approximately 7 fold in iron deficiency and 13 fold in
hereditary hemochromatosis. At the other end of the spectrum, there
was a 27 fold increase in urinary hepcidin in an endotoxemia model in
which healthy volunteers received E. coli lipopolysaccharide in the
amount of 2 ng/kg body weight i.v. Iron deficiency and hemochro-
matosis are associated with dramatically different amounts of storage
iron, however, both conditions are characterized by similarly very low
levels of hepcidin. Inflammation, in part secondary to upregulation of
IL-6, can be associated with very high concentrations of hepcidin with
consequently high levels of iron retention within macrophages. This
situation typically occurs, for example, in anemia of inflammation (i.e.
“anemia of chronic disorders”). The condition is sometimes described
as “functional iron deficiency” a term intended to indicate a decreased
availability of iron for erythropoiesis, despite a state of macrophage
iron overload. The reported association of inflammation and ather-
ogenesis may be in part related to impaired clearance of iron from
plaque macrophages resulting from high inflammation-induced levels
of hepcidin [7].
9. Genetic hemochromatosis and defective iron retention in the
macrophage
Genetic hemochromatosis is another factor that could strongly
influence the iron concentration of arterial plaque. Because HFE
mutations are almost always associated with very low hepcidin
concentrations and consequently with decreased retention of iron by
the macrophage [71,72], it appears likely that these mutations may,
counter-intuitively, cause more rapid clearance of iron from arterial
lesions. The classic finding in inherited hemochromatosis is misplaced
hepatic iron. The disease is associatedwith iron loading of hepatocytes
and a relative lack of iron in the normal reticuloendothelial sites, i.e.
within Kupffer cells. Hepcidin has emerged as amajor regulator of iron
distribution in the body. Decreased levels of hepcidin, especially the
very low levels associated with both iron deficiency anemia and with
genetic hemochromatosis, have the dual effect of enhancing iron
absorption from gut and simultaneously allowing release of iron from
storage sites, e.g. from macrophages.
The rate of iron release from arterial plaque macrophages in those
with HFE mutations has not been specifically examined, to my
knowledge. It is well known that the very low levels of hepcidin
observed in iron deficiency mediate the release of iron from
essentially all storage sites for iron mobilization to support erythro-
poiesis in the marrow. There is no reason to believe that iron in
intralesional macrophages is exempt from this mobilization process.
Indeed, animal studies showing decreased plaque area in association
with experimental arterial iron reduction [18,31,37] strongly support
the possibility that such arterial iron is just as mobilizable as it is from
other iron-storage locations in the body.
The large increase in body iron that can be seen especially in the
homozygous form of the disease may enhance susceptibility to
reperfusion injury and may also diffusely cause arterial intimal
thickening, while at the same time affording some specific protection
from iron induced plaque vulnerability. Many unanswered questions
remain on the impact of HFE mutations on arterial iron levels, plaque
stability, intimal proliferation and endothelial function. The apparent
lack of increased risk for arterial structural lesions in genetic
hemochromatosis [74] has often been cited as evidence against the
iron hypothesis [7,75]. However, the effects of extremely low hepcidin
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levels on lowering atherosclerotic plaque iron may explain how iron
can have an important role in atherogenesis yet paradoxically not
cause an increased prevalence of atherosclerosis in inherited iron
overload [7].
10. The FeAST trial
Findings of a first randomized trial of mild iron reduction therapy in
elderly patients with established peripheral vascular disease (the
“FeAST” trial) have been recently reported [9,76,77]. The trial assessed
the potential benefit of mild iron reduction therapy in secondary
prevention of cardiovascular disease. It was therefore not a fully valid
test of primary prevention as postulated by the iron hypothesis. No
overall statistically significant cardiovascular benefit was found. How-
ever, in the youngest quartile at entry there were highly significant
reductions in all cause mortality and in combined death plus non-fatal
myocardial infarction and stroke in association with iron reduction
therapy. Age was a prespecified stratification variable for randomiza-
tion. In all age quartiles, iron reduction therapy was associated with a
highly significant reduction in cancer mortality vs control patients.
The FeAST trial may have failed to observe a cardiovascular benefit
from iron reduction in older subjects because the study design
intentionally disallowed achievement of full iron depletion. Participants
in FeAST who were randomized to undergo iron reduction experienced
a decrease in mean serum ferritin from 122.5 ng/mL to 79.7 ng/mL.
Those with iron reduction ended the observation period with stored
iron levels substantially higher than those observed in menstruating
women who typically have serum ferritin values below 30 ng/mL.
In the FeAST trial, there was also no attempt to directly measure
arterial iron concentration or the effects of the iron reduction
intervention on this parameter. Therefore the trial results do not
directly address the role of plaque iron in atherogenesis. However, it
provides important information for a future trial of induced iron
depletion or iron deficiency on plaque iron and clinical events. It
provides important reassurance of the safety of iron reduction therapy
even in patients with established atherosclerotic disease. The
improved survival of the youngest quartile at entry suggests that
iron reduction with lower iron-storage targets and beginning at an
earlier age might prove more beneficial. It is also reassuring that even
this modest level of iron reduction was significantly associated with
lower cancer mortality in subjects of all ages. There was a 36.7% lower
risk of cancer occurrence (p=0.023) and a 68.6% lower cancer
mortality (p=0.003) compared to control patients [78,79].
11. Iron in arterial plaque: A modifiable risk factor for
atherosclerosis
These findings from animal models of atherosclerosis and from
studies of human atherosclerotic plaque provide support for the
concept that elevated arterial iron levels play a significant role in the
pathogenesis of atherosclerosis. Both the animal studies and long
clinical experience with the effects of iron deficiency anemia on
storage iron show that iron in arterial plaque can be mobilized for
erythropoiesis and thereby reduced in concentration. It should be
feasible to achieve the normally low iron concentration of healthy
arterial tissue and hold it at low levels indefinitely by induction and
maintenance of reduced total body iron. The degree and duration of
iron reduction required in humans to completely normalize athero-
sclerotic plaque iron concentrations to that of healthy arterial tissue is
a key question that must be addressed in future studies. The
demonstration that carotid plaque iron can be quantified by a
noninvasive, noncontrast magnetic resonance based T2⁎ measure-
ment [68] suggests one method by which plaque iron can be
monitored in future studies to address this key question. In addition,
how much iron reduction therapy would be required for primary
prevention of plaque formation and possibly for decreasing the size
and/or vulnerability of existing atherosclerotic plaque will require
future human studies. It is possible that significant benefit might be
achieved by induction of iron depletion, defined as the absence of
storage iron without anemia. Or, induction of mild iron deficiency
anemia may be required for maximal benefit.
12. Concluding comment: Is stored iron safe?
Suggesting that one disorder, i.e. atherosclerotic plaque, might be
treatable by the induction of a second disorder, i.e. iron depletion, may
be seen as a controversial proposal largely because there is a deeply
held and widely prevalent assumption that iron in storage is
inherently safe. The assumption is based ultimately on decades old
traditional medical practices rather than on appropriately designed
rigorous clinical trials. It has been previously noted [14] that “A benefit
of iron depletion can only be rigorously demonstrated in relation to
the state of iron in excess of needs (ie, the condition of having iron in
storage). It has not been widely appreciated that the safety of stored
iron can only be shown with clarity in studies of the same design.
Absence of proof that iron depletion is beneficial implies an absence of
proof of the safety of stored iron. Because of the deeply rooted
assumption that stored iron is safe, appropriate trials to rule out the
potential hazards of iron stores have not been undertaken.”
Among affluent populations, in the presence of plentiful dietary
iron and in the absence of prevalent parasites that cause occult
bleeding, iron is stored in the body in excess of needs. Under these
conditions, unless there is some other source of chronic iron loss, iron
availability is generally not a factor that limits growth rate or
achievement of maximal hemoglobin levels. However, this does not
prove that acquisition of stored iron is optimal for long term survival.
The analogy of caloric restriction is instructive. Among affluent
populations, the availability of an abundant supply of high calorie
foods is associated with maximal growth rates and prevalent obesity.
A gross excess of calories may be optimal for growth rate andmaximal
achieved adult weight and height, but not for long term survival. The
optimal caloric intake for longevity in animal experiments is
substantially smaller than ad libitum intakes in the presence of
caloric excess. Regulatory processes may have evolved that tend to
assure retention of an excess of calories in the form of fat deposition
against the possibility of future famine. A similar pattern may have
evolved with respect to iron retention. The accumulation of an excess
of iron beyond needs may have favored survival during human
evolution under conditions of limited iron availability. Under affluent
conditions, these processes may guarantee that iron in excess of the
optimum for longevity is retained. As with caloric intake, there may be
two optima for iron intake: a high level to achieve maximal growth
and hemoglobin level, and a significantly lower level to achieve
maximal longevity. Experimental strategies to establish the funda-
mental safety of storage iron should include studies on the effects of
iron restriction on longevity [14].
Roles for iron have been proposed in a broad range of serious
disorders including vascular disease [1], cancer [79–82], diabetes
[19,83,84], infectious diseases [85], neurodegenerative diseases [86–
88] and the process of senescence [6,89–91]. There is a critical need to
rethink the assumption (an assumption based on traditional medical
practices rather than rigorous testing) that stored iron is safe until
proved otherwise. Future studies on the role of iron in atherogenesis
and plaque vulnerability should not be compromised by perceived
ethical constraints based solely on this unproven assumption. Due
consideration must be given to the risk of failing to detect a
significant benefit because of inadequate iron reduction protocols in
future trials.
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